Close
RNS Number : 0505U
ValiRx PLC
24 July 2020
 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Broker Option - Fully Subscribed

 

London, UK., 24 July 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces that, further to the announcement made at 3.02pm on 23 July 2020, the Broker Option - a facility to allow existing shareholders to participate in the Fundraise on similar terms to the Placing announced, has been fully subscribed for by existing shareholders of the Company.

 

The Broker Option has raised £300,700 at a price of 7.5 pence per share through the issue of 4,009,334 new ordinary shares.

 

In the announcement made at 3.02pm on 23 July 2020 the shareholding of Gerry Desler, Chief Financial Officer of the Company, following the Subscription was erroneously stated as 1,941,875 representing 3.6% of the enlarged share capital.  The shareholding following the Subscription should have stated 81,667 representing 0.2% of the enlarged share capital.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Suzanne Dilly

Suzanne.Dilly@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker

Tel: +44 (0) 20 7469 0930

 

Notes for Editors

 

About ValiRx

ValiRx PLC accelerates the development of innovative medicines that enhance patient experience.  We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEKKQBNDBKDQOB